Bayer

[NewB76]

MT Newswires) -- Germany's Bayer (BAYN.F) secured fast track designation from the US Food and Drug Administration for asundexian in the potential treatment for secondary prevention in patients with a non-cardioembolic ischemic stroke.

The oral inhibitor of Factor XIa is also being investigated for two additional conditions of irregular heartbeat and heart attack, with an ongoing phase two trial in all three indications, according to a Thursday release.

[And its gone!]

BUZZ-Bayer 'well positioned' amid current uncertainties, Jefferies initiates at 'buy'
11:45 (14-03) - Bron: Reuters
** Jefferies initiates coverage of Bayer AG with
a "buy" rating as it believes the company is moving in the right
direction and is "well positioned" through present-day
uncertainties
** The broker says agriculture fundamentals are improving,
pricing is coming and FX is a meaningful tailwind
** "With defensive earnings, limited Russia and Ukraine
exposure, just 31% sales in Europe, low energy intensity, an
undemanding valuation and many catalysts, shares can
outperform", says Jefferies
** Glyphosate litigation, pharma pipeline updates and
strategic change are all further potential catalyst, adds the
broker
** Jefferies notes shares are priced at a 32% discount to
peers even assuming 7 billion euro remains for glyphosate
litigation
** The brokerage sets the price target at EUR 64
** Out of 27 analysts that cover Bayer AG, 19 rate the stock
"strong buy" or "buy"

(Reporting by Olga Beskrovnova)
(([email protected]))

[NewB76]

In his latest research note, analyst Michael Leuchten confirms his positive recommendation. The broker UBS is keeping its Buy rating. The target price is unchanged at EUR 90.

[And its gone!]

* Bayer AG : Liberum raises target price to EUR 82 from EUR 74

[And its gone!]

* Bayer AG : Citigroup raises price target to EUR 91 from EUR 70

[NewB76]

Betreffende Bayer
https://www.hsbc-zertifikate.de/home/da ... &analyse=1

[NewB76]

nieuws uit de USA
https://www.reuters.com/legal/governmen ... 022-03-21/

[And its gone!]

CORRECTED-Bayer reaches $80 mln PCB contamination settlement with Ohio
19:27 (24-03) - Bron: Reuters
(Corrects in paragraphs 5-6 to show there are about 2,500
members eligible for the class action, not thousands of separate
lawsuits)
By Tom Hals
March 24 (Reuters) - Bayer AG reached an $80
million settlement with Ohio to resolve environmental damage
allegedly caused by polychlorinated biphenyls, or PCBs, made by
the company's Monsanto business, the state attorney general said
on Thursday.
The funds from the German company, which did not admit
liability, will be used for environmental cleanup, the attorney
general said.
Monsanto, which Bayer acquired for $63 billion in 2018,
never manufactured PCBs in Ohio or discharged them into Ohio
waterways, Bayer said in a statement.
PCBs were once used widely to insulate electrical equipment,
and were used in carbonless copy paper, caulking, floor finish
and paint. They were outlawed by the U.S. government in 1979
after being linked to cancer.
Bayer has been trying to resolve a number of lawsuits
related to Monsanto's PCBs, which were used in commercial
products from 1935 until 1977, when Monsanto voluntarily ceased
production.
In addition to reaching legal settlements with states, the
company reached a $648 million proposed class action settlement
with about 2,500 cities and other local governments eligible as
members of the class. Last week the agreement received
preliminary approval from a federal judge.
Class members must decide whether to support the deal,
object to the terms or opt out and pursue their own case, as the
city of Los Angeles did earlier this month.
Bayer can withdraw from the settlement if more than 2% of
the class members opt out.
Bayer also faces personal injury cases stemming from PCB
exposure.
Two separate juries last year awarded a combined $247
million in damages stemming from exposure in a school in
Washington state. Bayer said the evidence showed the plaintiffs
were not exposed to unsafe levels of PCBs and the company said
it planned to appeal both verdicts.

(Reporting by Tom Hals in Wilmington, Delaware; Editing by
Susan Fenton)
(([email protected]; +1 610 544 2712; Reuters
Messaging: [email protected]))

[NewB76]

MT Newswires) -- Bayer (BAYN.F) said Monday it secured marketing authorization for its chronic kidney disease and type 2 diabetes drug Kerendia from the Japanese Ministry of Health, Labour, and Welfare.

The approval is based on the results from phase 3 studies that demonstrated positive kidney and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes.

Kerendia, which was granted marketing authorization by the European Union in February, is currently under review in several other countries.

[NewB76]

Berlin, April 3, 2022 – Bayer today announced positive data from the PACFIC-AF trial which compared the safety of the investigational, oral Factor XIa (FXIa) inhibitor asundexian with apixaban (a non-vitamin K antagonist oral anticoagulant) in patients with atrial fibrillation (AF). The results found that the bleeding rate for the primary endpoint (ISTH major and clinically relevant non-major bleeding) was reduced by 67% (incidence proportion of 0.33**) in patients receiving asundexian compared to those receiving apixaban. By selectively modulating coagulation, once-daily FXIa inhibitor asundexian is being investigated to become a new treatment option in thrombosis prevention. The findings were presented today at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22), and simultaneously published in The Lancet.